Categories: News

Edison Issues Report on Noctiluca (NCL)

London, United Kingdom–(Newsfile Corp. – January 21, 2026) – Edison issues report on Noctiluca (WSE: NCL).

Noctiluca is a dynamic advanced materials company specialising in OLED materials for displays and other photonics applications. It has a growing base of engagements with key players globally and is now seeing a significant acceleration driven by the breakthrough performance of its NCEIL-4 material, which has shown a 100% improvement in OLED lifetime across multiple applications. Noctiluca is working with eight of the top 10 display manufacturers, the most advanced being a joint development project with Guangdong Juhua (TCL Group) and the world’s largest telecommunications equipment vendor, which has progressed quickly to pre-production testing. The company appears to be on course to deliver a significant inflection in operationally leveraged growth from 2028.

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website www.edisongroup.com.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

enquiries@edisongroup.com

+44 (0)20 3077 5700

Connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281086

Staff

Recent Posts

University Medical Center Southern Nevada Becomes First Hospital in Nevada to Earn Magnet Recognition

Prestigious designation recognizes excellence in nursing, patient care, and clinical outcomesLAS VEGAS, Jan. 24, 2026…

2 hours ago

Direct Meds NAD+ Injections Consumer Report 2026: Comparing Supplement and Peptide Alternatives, Dosage, Benefits & Side Effects

A consumer-focused examination of NAD+ injections, NAD+ supplements, NAD+ peptides, NAD+ dosage protocols, documented NAD+…

2 hours ago

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today…

2 hours ago

Nexalin Technology Receives Nasdaq Listing Status Notification

HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”…

2 hours ago

MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity

TOKYO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; President…

2 hours ago